



SAUDI FELLOWSHIP TRAINING PROGRAM ADULT STEM CELL TRANSPLANTATION

Final Written Examination

Examination Format:

A Saudi subspecialty fellowship final written examination shall consist of one paper with 80-120 Single Best Answer MCQs. 10% unscored items can be added for pretesting purposes.

Passing Score:

1. The passing score is 70%.
2. If the percentage of candidates passing the examination before final approval is less than 70%, the passing score must be lowered by one mark at a time aiming at achieving 70% passing rate or 65% passing score whichever comes first. Under no circumstances can the passing score be reduced below 65%.





Suggested References:

- 1- Thomas' Hematopoietic Cell Transplantation - text book. Stephen J. Forman et al
- 2- EBMT handbook. Enric Carreras et al.
- 3- Hematopoietic stem cell transplantation: A handbook for clinicians. AABB. John R. Wingard et al
- 4- Hematopoietic stem cell transplantation in clinical practice - text book. Jennifer G. Treleaven et al
- 5- ASH - SAP. American Society of Hematology. 8th edition.
- 6- Updated Review articles related to the field of stem cell transplantation in relevant established journals. Examples of such journals include, amongst others, BMT-Nature; Transplantation and Cellular Therapy – ASTCT; Blood; Lancet Hematology.

Note:

This list is intended for use as a study aid only. SCFHS does not intend the list to imply endorsement of these specific references, nor are the exam questions necessarily taken solely from these sources.





Blueprint Outlines:

| No. | Sections | Percentage |
|--------------|---|-------------|
| 1 | Transplant Indications | 10% |
| 2 | Conditioning Regimens and Stem Cell Sources | 10% |
| 3 | Stem Cell Mobilizations/Collections | 10% |
| 4 | BMT Lab (HLA, Stem Cell Enumeration, Stem Cell Processing, Harvest, Monitoring, Blood Bank) | 10% |
| 5 | Pre And Post Transplant Recipient/Donor Evaluation | 7% |
| 6 | GVHD Prophylaxis | 6% |
| 7 | GVHD | 10% |
| 8 | Transplant Infectious Complications | 7% |
| 9 | Other Transplant Complications | 7% |
| 10 | CAR T Cell Therapy/Other Cellular and Immunotherapies | 7% |
| 11 | Hematological Malignancies Management | 5% |
| 12 | BMT Quality | 5% |
| 13 | Miscellaneous | 6% |
| Total | | 100% |

Note:

- Blueprint distributions of the examination may differ up to +/-5% in each category.
- Percentages and content are subject to change at any time. See the SCFHS website for the most up-to-date information.
- Research, Ethics, Professionalism and Patient Safety are incorporated within various domains.

